Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Anhui Anke Biotechnology

Biotech & Life Sciences · Hefei, China · Founded 1994 · IPO 2009 Unicorn

Anhui Anke Biotechnology is a biopharmaceutical high-tech enterprise based in China

Valuation
$1.82B
Market cap · May/2026
Revenue
$364M
Latest reported FY
EBITDA
$135M
Latest reported FY

Investors

2 investors on Anhui Anke Biotechnology's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Good Capital Group
Series B+ 1 investor entered at this stage
Anhui Institute of Biology

Global footprint

Where Anhui Anke Biotechnology has talent and traffic

Workforce by country
2 countries with
team presence
🇨🇳 China94.7%
🇳🇿 New Zealand5.3%
2 countries shown
Web traffic by country
2.3K monthly visits
across markets
🇺🇸 United States91.3%
🇦🇺 Australia8.7%
Top 2 markets shown

Patent intelligence

$1M patent portfolio · 24 active families

Estimated portfolio value
$1M
0.08% of market cap · 1395.7× smaller than top peer Ablynx ($2B)
24 active patent families
Where Anhui Anke Biotechnology innovates Molecular biologyChemistryAntiendomysial antibodiesMedicineInterferon

Where Anhui Anke Biotechnology concentrates vs peers

Each axis is a top-10 topic across Anhui Anke Biotechnology and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Anhui Anke Biotechnology's 3 investments and acquisitions.

Every disclosed deal where Anhui Anke Biotechnology appeared as a backer or acquirer, 2017–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Anhui Anke Biotechnology's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Anhui Anke Biotechnology deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Anhui Anke Biotechnology's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Anhui Anke Biotechnology

        An AI-synthesized read of the highest-engagement posts about Anhui Anke Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Anhui Anke Biotechnology on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.